Overview
McLeod neuroacanthocytosis syndrome is an X-linked disorder characterized by progressive neurodegeneration, predominantly affecting the basal ganglia, along with erythrocyte acanthocytosis. It manifests primarily with movement disorders such as chorea and dystonia, often accompanied by psychiatric and cognitive symptoms 1.Diagnosis
Clinical Presentation: Chorea, dystonia, psychiatric symptoms, and cognitive decline 1.
Laboratory Tests: Erythrocyte acanthocytosis can be observed but is not always present 1.
Genetic Testing: Identification of mutations in the XK gene confirms the diagnosis 1.
Neuroimaging: MRI may show characteristic changes in basal ganglia structures 1.Management
First-Line Treatments:
- Antichoreic Agents: Dopamine receptor antagonists (e.g., haloperidol) for chorea 1.
- Antidystonic Medications: Baclofen or benzodiazepines for dystonia 1.
Adjunctive Therapies:
- Psychiatric Support: Antipsychotics or antidepressants for psychiatric symptoms 1.
- Physical and Occupational Therapy: To manage motor symptoms and improve function 1.Special Populations
Pediatrics: Early onset can present challenges in diagnosis and management; genetic counseling is crucial 1.
Comorbidities: Psychiatric comorbidities are common and require integrated care 1.Key Recommendations
Confirm diagnosis through genetic testing for XK gene mutations (Evidence: Strong 1).
Initiate treatment with dopamine receptor antagonists for chorea and baclofen for dystonia (Evidence: Moderate 1).
Provide comprehensive psychiatric support due to frequent psychiatric symptoms (Evidence: Expert opinion 1).References
1 Walker RH, Jung HH, Danek A. Neuroacanthocytosis. Handbook of clinical neurology 2011. link